Login to Your Account



In The Clinic NEWS

CEO Jeff Jonas told BioWorld Today the regulatory path OK'd by the FDA for Sage Therapeutics Inc.'s drug SAGE-547 hurries the potential availability in a severe unmet need by at least a year, and "shows the strength of the data package" brought to gatekeepers who said yes to a plan that the company had in mind all along.

SAN DIEGO – Despite four decades of clinical research in AML, the current standard-of-care induction therapy remains the 7 + 3 regimen, usually referring to seven days of cytarabine plus three days of daunorubicin, said Harry Erba.

SAN DIEGO – AML has joined the ranks of other cancers now getting the precision medicine treatment, so to speak.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: